Cibc World Markets Has Trimmed By $26.60 Million Its Autodesk (ADSK) Stake; 7 Analysts Bullish Evoke Pharma, Inc. (EVOK)

April 19, 2018 - By Vivian Park

Evoke Pharma, Inc. (NASDAQ:EVOK) Logo

Among 9 analysts covering Evoke Pharma (NASDAQ:EVOK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Evoke Pharma had 22 analyst reports since August 20, 2015 according to SRatingsIntel. Northland Capital initiated the shares of EVOK in report on Wednesday, March 16 with “Outperform” rating. The rating was upgraded by Rodman & Renshaw to “Buy” on Thursday, January 5. The rating was maintained by H.C. Wainwright on Wednesday, November 29 with “Buy”. The rating was maintained by H.C. Wainwright on Monday, April 2 with “Buy”. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) has “Buy” rating given on Thursday, August 20 by Brean Capital. The firm has “Buy” rating by Laidlaw given on Monday, January 30. Ascendiant Capital maintained the shares of EVOK in report on Monday, March 14 with “Buy” rating. H.C. Wainwright initiated Evoke Pharma, Inc. (NASDAQ:EVOK) on Thursday, October 1 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 6 report. As per Thursday, March 8, the company rating was maintained by FBR Capital. See Evoke Pharma, Inc. (NASDAQ:EVOK) latest ratings:

02/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain
08/03/2018 Broker: FBR Capital Rating: Buy New Target: $5.0 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
29/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Buy New Target: $10.0 Maintain
24/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain

Cibc World Markets Corp decreased Autodesk Inc (ADSK) stake by 80.19% reported in 2017Q4 SEC filing. Cibc World Markets Corp sold 255,743 shares as Autodesk Inc (ADSK)’s stock rose 23.51%. The Cibc World Markets Corp holds 63,163 shares with $6.62 million value, down from 318,906 last quarter. Autodesk Inc now has $29.10B valuation. The stock decreased 0.45% or $0.5963 during the last trading session, reaching $133.2737. About 166,132 shares traded. Autodesk, Inc. (NASDAQ:ADSK) has risen 50.18% since April 19, 2017 and is uptrending. It has outperformed by 38.63% the S&P500.

Investors sentiment decreased to 1.63 in Q4 2017. Its down 2.87, from 4.5 in 2017Q3. It turned negative, as 4 investors sold Evoke Pharma, Inc. shares while 4 reduced holdings. 8 funds opened positions while 5 raised stakes. 2.71 million shares or 35.53% less from 4.20 million shares in 2017Q3 were reported. California Public Employees Retirement Systems holds 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 36,700 shares. Wells Fargo Mn stated it has 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). State Treasurer State Of Michigan invested 0.01% in Evoke Pharma, Inc. (NASDAQ:EVOK). Susquehanna Intl Grp Inc Limited Liability Partnership stated it has 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Moreover, Bankshares Of Ny Mellon has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK) for 24,908 shares. Morgan Stanley holds 5,350 shares. Moreover, Geode Mgmt Limited Liability Company has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK). Citigroup reported 500 shares. The Germany-based Deutsche National Bank Ag has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Macquarie Group Ltd holds 0% or 14,300 shares in its portfolio. 683 Capital Mngmt Lc, New York-based fund reported 114,300 shares. Art Ltd Liability owns 12,368 shares for 0% of their portfolio. 65,529 are held by Blackrock Inc. Sphera Funds Management holds 769,149 shares or 0.2% of its portfolio. Virtu Fincl Limited Liability Corporation reported 21,457 shares stake.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $38.11 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

The stock increased 1.65% or $0.04 during the last trading session, reaching $2.46. About 3,176 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has declined 28.33% since April 19, 2017 and is downtrending. It has underperformed by 39.88% the S&P500.

Investors sentiment decreased to 1.08 in Q4 2017. Its down 0.34, from 1.42 in 2017Q3. It dived, as 46 investors sold ADSK shares while 171 reduced holdings. 84 funds opened positions while 151 raised stakes. 204.78 million shares or 0.77% less from 206.38 million shares in 2017Q3 were reported. Illinois-based Calamos Advsrs Limited Liability Company has invested 0.02% in Autodesk, Inc. (NASDAQ:ADSK). Ameritas Investment Ptnrs accumulated 0.04% or 8,870 shares. Etrade Cap Management Ltd Liability holds 0.04% or 11,338 shares in its portfolio. Nordea Invest Management Ab reported 0.02% stake. Gsa Cap Prtn Llp has 5,177 shares. Gilder Gagnon Howe Com Ltd Liability Com owns 834,649 shares. Salem Inv Counselors holds 0.11% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK) for 9,625 shares. Whittier Trust, California-based fund reported 561 shares. The France-based Natixis has invested 0.01% in Autodesk, Inc. (NASDAQ:ADSK). Vident Investment Advisory Limited Liability holds 174,407 shares. State Of New Jersey Common Pension Fund D stated it has 0.03% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Parnassus Invests Ca stated it has 1.80M shares or 0.74% of all its holdings. 64,220 are held by State Treasurer State Of Michigan. Suntrust Banks owns 14,097 shares or 0.01% of their US portfolio. Virtu Financial Ltd Liability Com invested in 8,181 shares.

Cibc World Markets Corp increased Carmax Inc Com (NYSE:KMX) stake by 12,587 shares to 41,089 valued at $2.64M in 2017Q4. It also upped Incyte Corp (NASDAQ:INCY) stake by 13,107 shares and now owns 54,661 shares. United Rentals Inc Com (NYSE:URI) was raised too.

Among 27 analysts covering Autodesk Inc. (NASDAQ:ADSK), 18 have Buy rating, 3 Sell and 6 Hold. Therefore 67% are positive. Autodesk Inc. had 124 analyst reports since August 4, 2015 according to SRatingsIntel. Canaccord Genuity maintained the shares of ADSK in report on Monday, June 19 with “Buy” rating. The firm earned “Buy” rating on Wednesday, March 7 by Guggenheim. The firm has “Buy” rating given on Thursday, August 20 by Cowen & Co. The stock has “Hold” rating by Canaccord Genuity on Friday, August 26. RBC Capital Markets maintained Autodesk, Inc. (NASDAQ:ADSK) rating on Sunday, October 8. RBC Capital Markets has “Buy” rating and $125.0 target. Wedbush initiated Autodesk, Inc. (NASDAQ:ADSK) on Friday, September 9 with “Neutral” rating. Canaccord Genuity maintained the shares of ADSK in report on Tuesday, March 6 with “Buy” rating. The company was upgraded on Thursday, December 8 by Rosenblatt. Wells Fargo maintained Autodesk, Inc. (NASDAQ:ADSK) on Thursday, November 16 with “Buy” rating. The firm has “Neutral” rating given on Monday, August 31 by Citigroup.

Since March 7, 2018, it had 0 buys, and 8 selling transactions for $6.09 million activity. Shares for $77,981 were sold by Underwood Paul D. on Friday, March 16. 388 shares valued at $48,329 were sold by Di Fronzo Pascal W on Monday, April 2. Blum Steven M sold $2.53 million worth of stock. On Thursday, March 29 Anagnost Andrew sold $2.57M worth of Autodesk, Inc. (NASDAQ:ADSK) or 20,499 shares. The insider BEVERIDGE CRAWFORD W sold 1,500 shares worth $199,665.

Autodesk, Inc. (NASDAQ:ADSK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>